Takeda's Entyvio shows clinical benefits, irrespective of prior treatment: 3 notes

Takeda Pharmaceutical's Entyvio (vedolizumab) may improve clinical outcomes for patients suffering from ulcerative colitis, according to a study in Clinical Gastroenterology and Hepatology. These improved clinical outcomes were seen irrespective of a patient's treatment history.

The researchers evaluated the use of vedolizumab therapy in patients with ulcerative colitis, based on their treatment history with tumor necrosis factor antagonist therapy. The patients were divided into two cohorts: those who had never received TNF antagonist therapy and those who had undergone failed TNF antagonist therapy.

Here's what you need to know:

1. Approximately half of patients with ulcerative colitis do not have a successful response to TNF antagonist therapy.

2. The researchers found significantly greater clinical outcomes with vedolizumab therapy — regardless of treatment history with TNF antagonist therapy — when compared to placebo treatment.

3. There were no differences in adverse events between the study's treatment groups.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast